CD274 and cancer: LAG-3 inhibitors, together with CTLA-4 or PD-1/PD-L1 inhibitors, have been extensively explored in the different clinical trials for cancer therapy, which can not only avoid drug tolerance but also improve the clinical efficacy of LAG-3 inhibitors.